as drug-resistant epilepsy (DRE), represents a formidable challenge in the clinic with poor prognosis and heavy disease burden. [1] Resection or ablation of epileptogenic focus offers an important method for the treatment of focal DRE such as temporal lobe epilepsy (TLE). However, locoregional resective surgery is greatly impeded by postoperative complications and misconceptions. [2] Laser interstitial thermal therapy (LITT), which adopts 980 nm or 1064 nm second near-infrared (NIR-II) laser, can achieve comparable efficacy to traditional surgery while significantly reducing surgical complications, showing great prospects for photothermal therapy (PTT) of epilepsy. [3] However, the operating power of clinically approved PTT approaches including LITT is usually as high as 10 W. [4] Therefore, nonselective killing of lesions and surrounding healthy tissues is unavoidable. [4a,5] Photothermal agents (PTA) which could absorb light irradiation and exhibit photo-heat conversion effects substantially increase the selectivity of PTT. [5][6] Our previous study also revealed that polydopamine nanoparticles irradiated by 808 nm laser can precisely ablate the deep brain tissue without significant damage to the superficial tissues. [7] Despite great progress in the development of PTA, PTT relying solely on heating Photothermal therapy (PTT) has been approved clinically to ablate epileptogenic focus, while the clinical application of this approach is still hindered due to its limited selectivity and potential safety concerns related to extreme hyperthermia. Hypothermal PPT (HPTT) is a novel treatment modality employing mild hyperthermia to ablate abnormal cells, which has a distinctive advantage of minimal side effects on healthy tissues. The significantly elevated hydrogen peroxide (H 2 O 2 ) concentration in the epileptogenic zone provides a suitable microenvironment for selective chemodynamic therapy (CDT), which utilizes the Fenton reaction of H 2 O 2 and iron-based nanomaterials to generate cytotoxic free radicals. Herein, the authors report proof-ofconcept evidence that HPTT and CDT can be successfully integrated to ablate epileptogenic focus. A photothermal nanocatalyst ferrous disulfide nanoplatform is prepared for CDT of epilepsy. More importantly, the CDT efficacy is augmented by the second near-infrared irradiation-induced hyperthermia, leading to synergistic HPTT and CDT therapy. In vivo studies on pentylenetetrazole kindling epileptic rats show that the frequency and severity of epileptic attacks are remarkably suppressed after ablation of the epileptogenic focus. It is envisioned that this HPTT augmented CDT strategy may serve as a novel strategy for the treatment of focal epilepsy.